中华放射肿瘤学杂志
Thursday, Apr. 3, 2025   Home | Journal | Editorial | Instruction | Subscription | Advertisement | Academic | Index-in | Contact Us | Chinese
Chinese Journal of Radiation Oncology  2023, Vol. 32 Issue (2): 174-178    DOI: 10.3760/cma.j.cn113030-20211111-00457
Review Articles Current Issue| Next Issue| Archive| Adv Search [an error occurred while processing this directive] | [an error occurred while processing this directive]
Research progress on radiotherapy and radiation-associated adverse effects of high-risk neuroblastoma
Zhang Shidi, Bai Yongrui, Chen Haiyan
Department of Radiation Oncology, Ren Ji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200127, China
Download: PDF (0 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      Supporting Info
Abstract  High-risk neuroblastoma (NB) is highly aggressive and has poor prognosis. Treatment of NB mainly includes comprehensive therapies, of which radiotherapy serves as a part of consolidation therapy. For patients who receive complete resection of the primary lesion, usually an irradiation dose of 21-23.4 Gy is given; for patients with incomplete resection, further study focused on radiation dose is necessary. Recurrence is most commonly observed in the bone lesions involved at presentation. Currently, the principle of irradiation to the metastatic sites is to treat lesions where metaio-dobenzylguanidine (MIBG) uptake remains positive after induction chemotherapy, or those become negative uptake but still at high risk of recurrence. On the premise of lacking of MIBG imaging, positron emission tomography CT (PET-CT) may assist in screening for metastatic sites requiring irradiation. The late side effects of radiotherapy are mainly mild musculoskeletal abnormalities. No significant increase is observed in the incidence of second primary tumor during short-term follow-up.
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
Zhang Shidi
Bai Yongrui
Chen Haiyan
Key wordsNeuroblastoma      Radiotherapy      Primary lesions      Metastatic sites      Adverse effects     
Received: 11 November 2021     
Corresponding Authors: Chen Haiyan, Email: chenhaiyan1220@163.com   
Cite this article:   
Zhang Shidi,Bai Yongrui,Chen Haiyan. Research progress on radiotherapy and radiation-associated adverse effects of high-risk neuroblastoma[J]. Chinese Journal of Radiation Oncology, 2023, 32(2): 174-178.
Zhang Shidi,Bai Yongrui,Chen Haiyan. Research progress on radiotherapy and radiation-associated adverse effects of high-risk neuroblastoma[J]. Chinese Journal of Radiation Oncology, 2023, 32(2): 174-178.
URL:  
http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20211111-00457     OR     http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2023/V32/I2/174
  Copyright © 2010 Editorial By Chinese Journal of Radiation Oncology
Support by Beijing Magtech Co.ltd  support@magtech.com.cn